Inhibikase Therapeutics (NASDAQ:IKT – Get Free Report) and CorMedix (NASDAQ:CRMD – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends and earnings.
Risk & Volatility
Inhibikase Therapeutics has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500. Comparatively, CorMedix has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500.
Earnings & Valuation
This table compares Inhibikase Therapeutics and CorMedix”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Inhibikase Therapeutics | $260,000.00 | 966.05 | -$48.26 million | ($0.43) | -4.19 |
| CorMedix | $311.71 million | 1.85 | $163.05 million | $2.14 | 3.45 |
CorMedix has higher revenue and earnings than Inhibikase Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Inhibikase Therapeutics and CorMedix, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Inhibikase Therapeutics | 1 | 2 | 4 | 3 | 2.90 |
| CorMedix | 0 | 2 | 7 | 0 | 2.78 |
Inhibikase Therapeutics presently has a consensus price target of $4.75, indicating a potential upside of 163.89%. CorMedix has a consensus price target of $15.00, indicating a potential upside of 102.98%. Given Inhibikase Therapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe Inhibikase Therapeutics is more favorable than CorMedix.
Institutional & Insider Ownership
3.8% of Inhibikase Therapeutics shares are owned by institutional investors. Comparatively, 34.2% of CorMedix shares are owned by institutional investors. 7.1% of Inhibikase Therapeutics shares are owned by company insiders. Comparatively, 3.5% of CorMedix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Profitability
This table compares Inhibikase Therapeutics and CorMedix’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Inhibikase Therapeutics | N/A | -42.80% | -40.58% |
| CorMedix | 40.49% | 40.52% | 20.61% |
Summary
CorMedix beats Inhibikase Therapeutics on 9 of the 14 factors compared between the two stocks.
About Inhibikase Therapeutics
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
About CorMedix
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Receive News & Ratings for Inhibikase Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibikase Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
